In patients with moderate to severe psoriasis who also have obesity or type 2 diabetes, what is your approach to counseling them on the potential role of adjunctive GLP-1 receptor agonists in reducing overall psoriasis disease burden?
Is this a conversation you bring up, or do you defer completely to the PCP/endocrinologist as to whether there is a role for it?
Community PollStarted
How do you incorporate discussion of GLP-1 agonists in patients with psoriasis and obesity?
37 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Dermatology · UCONN
Answered on
I am a firm believer that these medications are key to maximizing therapeutic response in diseases like psoriasis and even more so in HS. They have been shown to reduce the production of inflammatory markers in both diseases. The Together PsO and PsA trials showed better PASI responses (including PA...
Join for free or sign in to see the full answer